carvedilol has been researched along with Hepatic Encephalopathy in 5 studies
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol treatment decreased the brain levels of oxidative stress markers and induced Nrf2/HO-1 pathway." | 5.72 | Carvedilol attenuates brain damage in mice with hepatic encephalopathy. ( Amirshahrokhi, K; Niapour, A, 2022) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "Carvedilol treatment decreased the brain levels of oxidative stress markers and induced Nrf2/HO-1 pathway." | 1.72 | Carvedilol attenuates brain damage in mice with hepatic encephalopathy. ( Amirshahrokhi, K; Niapour, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amirshahrokhi, K | 1 |
| Niapour, A | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Villanueva, C | 1 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 1 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 1 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 1 |
| Alvarado, E | 1 |
| Torres, F | 1 |
| Bosch, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carvedilol and Hepatic Encephalopathy
| Article | Year |
|---|---|
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
1 trial available for carvedilol and Hepatic Encephalopathy
2 other studies available for carvedilol and Hepatic Encephalopathy
| Article | Year |
|---|---|
Carvedilol attenuates brain damage in mice with hepatic encephalopathy.
Topics: Animals; Brain; Brain Injuries; Carvedilol; Hepatic Encephalopathy; Mice; NF-kappa B; Oxidative Stre | 2022 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |